Searchable abstracts of presentations at key conferences in endocrinology

ea0081oc11.2 | Oral Communications 11: Thyroid 2 | ECE2022

What you choose makes the difference: the first medical therapy for amiodarone-induced thyrotoxicosis has significant implications on cardiovascular events and hospitalizations

Cappellani Daniele , Cosentino Giada , Morganti Riccardo , Manetti Luca , Bartalena Luigi , Bogazzi Fausto

Context: Amiodarone is a widely used anti-arrhythmic medication, however associated with a 15-20% rate of thyroid adverse effects. Amiodarone-induced thyrotoxicosis (AIT) is a complex disease due to diagnostic difficulties and therapeutic challenges. AIT patients often receive initial therapy for thyrotoxicosis before admission to a referral center. Whether the first-line medical therapy (i.e. therapies for thyrotoxicosis at first diagnosis of AIT) may affect the outcome of AI...

ea0081ep774 | Pituitary and Neuroendocrinology | ECE2022

Cushing’s syndrome due to adrenocorticotropic hormone-secreting metastatic neuroendocrine pancreatic tumor: diagnostic workup and management

Cosentino Giada , Manetti Luca , Marconcini Giulia , Boggi Ugo , Marconcini Riccardo , Lupi Isabella , Cappellani Daniele , Urbani Claudio , Bogazzi Fausto

We report the clinical history of a 21-years old young female who, in February 2021, presented abdominal pain and biliary vomiting that lasted for two months. An esophagus-gastroduodenoscopy revealed a duodenal ulcerative lesion and proton pump inhibitory therapy was started with clinical benefit. One month later, the patient presented a facial acneiform rush with hirsutism for which she was referred to our attention. An abdominal MRI documented a well-circumscribed hyper-vasc...

ea0070aep332 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Immune checkpoint inhibitors (ICIs) and ‘Fulminant Diabetes’: Two emblematic cases

Sgro’ Daniele , Giannarelli Rosa , Aragona Michele , Viola Nicola , Cosentino Giada , Brancatella Alessandro , Latrofa Francesco , Del Prato Stefano , Santini Ferruccio , Marcocci Claudio , Lupi Isabella

Context: Programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) are key regulators in T-cell activation and tolerance. Nivolumab (PD-1 inhibitor) and Atezolizumab (PD-L1 inhibitor) are monoclonal antibodies approved for the treatment of several types of advanced cancers. Immune checkpoint inhibition caused by these drugs can result in immune-related adverse events (irAEs) New-onset diabetes mellitus has been reported in fewer than 1% of patients an...

ea0092ps2-15-01 | Hyperthyroidism | ETA2023

A prospective, observational study on the effect of an ablative vs a conservative approach for the treatment of graves’ hyperthyroidism in patients with moderate-to-severe, active graves’ orbitopathy

Cosentino Giada , Lanzolla Giulia , Comi Simone , Menconi Francesca , Rotondo Dottore Giovanna , Novella Maglionico Maria , Posarelli Chiara , Figus Michele , Elisei Rossella , Santini Ferruccio , Marino Michele

Objectives: Optimal treatment for Graves’ hyperthyroidism (GH) in patients with moderate-to-severe, active Graves’ orbitopathy (GO) remains to be established. There is debate on whether a conservative (antithyroid drugs, ATDs) or an ablative approach (radioactive iodine, RAI, or surgery, Tx)has to be preferred. The aim of the present study was to investigate whether these different approachesresult in a different outcome of GOfollowing intravenous glucocorticoids (iv...

ea0092ps3-24-02 | Thyroid Eye Disease | ETA2023

Long-Term outcome of moderate-to-severe, active graves’ orbitopathy following treatment with sirolimus (Ramamycin): results in a case series

Comi Simone , Lanzolla Giulia , Cosentino Giada , Menconi Francesca , Novella Maglionico Maria , Posarelli Chiara , Leni Lorenzo , Figus Michele , Elisei Rossella , Santini Ferruccio , Marino Michele

Objectives: Sirolimus is an immunosuppressive drug with anti-fibrotic and anti-proliferative activities. In a recent study, sirolimus (given off-label as a second-line treatment) was found to be associated with a better outcome of Graves’ orbitopathy (GO) at 6 months compared to the standard treatment (intravenous glucocorticoids). Here we investigated the effects of sirolimus over a longer period of time.Methods: The study design entailed data anal...